Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | FNTA | P49354 | 1/20 | 0.43 |
| ▸ | FNTB | P49356 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2438024 | 0.85 | GRM6 (0.48) | ALDH1A1MAPT | |
| SCHEMBL30867774 | 0.85 | GRM6 (0.48) | ALDH1A1MAPT | |
| SCHEMBL4900762 | 0.84 | RORC (0.46) | KDM4EALDH1A1CHRNB2CHRNA4MAPT | |
| SCHEMBL1817493 | 0.81 | KDM4E (0.67) | KDM4EPOLBALDH1A1TP53MDM2 | |
| SCHEMBL2031815 | 0.81 | KDM4E (0.67) | KDM4EPOLBALDH1A1TP53MDM2 | |
| SCHEMBL27930152 | 0.80 | CHRNB2 (0.46) | KDM4EPOLBALDH1A1TP53MDM2 | |
| SCHEMBL28290433 | 0.79 | KDM4E (0.55) | KDM4EPOLBTP53MDM2CHRNB2 | |
| SCHEMBL4629587 | 0.79 | CHRNB2 (0.44) | KDM4EPOLBALDH1A1TP53MDM2 | |
| SCHEMBL27712915 | 0.77 | SIGMAR1 (0.47) | ALDH1A1MAPT | |
| SCHEMBL31297396 | 0.76 | CHRNB2 (0.44) | KDM4EPOLBALDH1A1TP53MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207630-A1 | 2-Aminocarbonyl Substituted Piperazine or Diaza-Cyclic Compounds as Apoptosis Protein Inhibitors (Iap) Modulators | ECKL ROBERT | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207630-A1 | 2-Aminocarbonyl Substituted Piperazine or Diaza-Cyclic Compounds as Apoptosis Protein Inhibitors (Iap) Modulators | API5, BCL2, BIRC5 | KDM4E 3213/4885POLB 2103/4885ALDH1A1 3485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.